Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemia
Follows people with sickle cell disease or beta-thalassemia who received EDIT-301 over time.
Key facts
- Who runs it
- Editas Medicine, Inc.
- Where
- Atlanta, Aurora, Charleston, Charlotte, Cleveland, Columbus, Dallas, Fort Worth, Minneapolis, Nashville, New Haven, New York, Oakland, Philadelphia, and St. Petersburg, United StatesSee the 16 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
- Status
- Enrolling by invitation
- People taking part
- 54 people, planned
- Started
- 17 Jun 2024
- Expected to end
- Aug 2040
- Type of study
- Observational
- Treatments tested
- Safety and efficacy assessments
- Record updated
- 2 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with severe sickle cell disease or transfusion-dependent β-thalassemia who already received an EDIT-301 infusion in another study. It follows their safety and results over the long term.
- Age
- 12 to 50 years
- Sex
- All sexes can join.
- Disease stage
- Severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT).
- Earlier treatment
- Must have received an EDIT-301 infusion as part of a clinical study.
Main reasons for not taking part
- Still actively taking part in an EDIT-301 treatment study and not yet ready for long-term follow-up in this study
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participant must have received an EDIT-301 infusion as part of a clinical study
- Participant or legal representative/guardian (if applicable) must sign and date the informed consent form (ICF) or assent, if applicable for this long-term follow-up study
Who cannot take part
- Participant is still actively enrolled in an EDIT-301 treatment study and has not yet met eligibility for long term follow-up in this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 50 years old?
Where in United States
Also in 1 other country, 2 sites
- Children's Healthcare of AtlantaAtlanta, United StatesEnrolling by invitation
- Children's Hospital ColoradoAurora, United StatesEnrolling by invitation
- Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
- Atrium HealthCharlotte, United StatesEnrolling by invitation
- Cleveland ClinicCleveland, United StatesEnrolling by invitation
- Nationwide Children's HospitalColumbus, United StatesEnrolling by invitation
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesEnrolling by invitation
- Cook Children'sFort Worth, United StatesEnrolling by invitation
- University of MinnesotaMinneapolis, United StatesEnrolling by invitation
- Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood CancersNashville, United StatesEnrolling by invitation
- Smilow Cancer HospitalNew Haven, United StatesEnrolling by invitation
- Columbia University Medical CenterNew York, United StatesEnrolling by invitation
- Columbia University Medical Center - Department of PediatricsNew York, United StatesEnrolling by invitation
- UCSF Benioff Children s HospitalOakland, United StatesEnrolling by invitation
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
- Johns Hopkins All Children's HospitalSt. Petersburg, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
The group in the trial
- All participants
All participants who complete or discontinue one of the parent studies (EM-SCD-301-001 or EDIT-301-BThal-001)
Treatment: Safety and efficacy assessments
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
- Plain-language title
- Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06363760, who can take part
- Record updated
- 2 April 2025